NewGenIvf Group (NASDAQ:NIVF) Director Kong Yiu Cheung Acquires 222,223 Shares of Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung purchased 222,223 shares of the stock in a transaction dated Thursday, May 28th. The shares were purchased at an average price of $1.50 per share, with a total value of $333,334.50. Following the completion of the acquisition, the director owned 222,223 shares of the company’s stock, valued at approximately $333,334.50. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Kong Yiu Cheung also recently made the following trade(s):

• On Monday, July 27th, Kong Yiu Cheung acquired 2,500,000 shares of NewGenIvf Group stock. The stock was acquired at an average cost of $1.00 per share, with a total value of $2,500,000.00.
• On Thursday, June 18th, Kong Yiu Cheung acquired 500,000 shares of NewGenIvf Group stock. The shares were bought at an average cost of $1.33 per share, with a total value of $665,000.00.

NewGenIvf Group Trading Down 1.4%

Shares of NIVF stock opened at $1.33 on Wednesday. NewGenIvf Group Limited has a one year low of $1.15 and a one year high of $1,539.00. The company has a 50 day moving average price of $2.96 and a 200 day moving average price of $11.34. The company has a quick ratio of 2.98, a current ratio of 3.12 and a debt-to-equity ratio of 0.16.

Analysts Set New Price Targets

A number of brokerages have issued reports on NIVF. Weiss Ratings reaffirmed a “sell (d)” rating on shares of NewGenIvf Group in a research report on Friday, July 24th. Wall Street Zen raised shares of NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.